Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Free Report) – Stock analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Sensei Biotherapeutics in a research note issued to investors on Monday, June 22nd. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.78) for the quarter. HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($1.06) EPS, FY2028 earnings at ($3.19) EPS, FY2029 earnings at ($3.16) EPS and FY2030 earnings at ($3.07) EPS.
Other equities research analysts also recently issued research reports about the stock. Weiss Ratings began coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. BTIG Research upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.00.
Sensei Biotherapeutics Stock Performance
FTH opened at $23.19 on Tuesday. Sensei Biotherapeutics has a twelve month low of $6.32 and a twelve month high of $36.76.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.
Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.
Further Reading
- Five stocks we like better than Sensei Biotherapeutics
- SpaceX Valuation Loses Altitude as AI Risks Mount
- Copa Holdings May Be the Airline Stock Built to Break Out
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
